RedHill Biopharma Ltd.
RDHL
$1.64
-$0.09-5.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.84% | -33.84% | 80.88% | 80.88% | -302.89% |
| Total Depreciation and Amortization | -59.81% | -59.81% | -50.37% | -50.37% | 100.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 92.09% | 92.09% | -89.71% | -89.71% | -104.61% |
| Change in Net Operating Assets | -132.84% | -132.84% | 102.19% | 102.19% | 108.52% |
| Cash from Operations | 18.92% | 18.92% | 82.36% | 82.36% | 70.80% |
| Capital Expenditure | -300.00% | -300.00% | -100.00% | -100.00% | 92.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -300.00% | -300.00% | -172.73% | -172.73% | 92.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 54.35% | 54.35% | 62.12% | 62.12% | 29.35% |
| Issuance of Common Stock | -58.27% | -58.27% | -100.00% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -91.15% | -91.15% | -98.66% |
| Cash from Financing | -58.75% | -58.75% | -96.89% | -96.89% | 131,566.67% |
| Foreign Exchange rate Adjustments | 250.00% | 250.00% | 178.95% | 178.95% | -116.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.52% | -202.52% | -86.41% | -86.41% | 108.08% |